Recognition and degradation of mRNA by nonsense-mediated decay
无义介导的衰变对 mRNA 的识别和降解
基本信息
- 批准号:8499372
- 负责人:
- 金额:$ 28.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-20 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressBeliefBindingBinding ProteinsBiological AssayCell modelCellsCore ProteinDataDiscriminationDisputesElementsEnsureEukaryotic CellGene ExpressionGene MutationGeneticGoalsGrantHealthHereditary DiseaseHumanHuman GeneticsIndividualLeadLeftLightMediatingMessenger RNAMetabolismModelingMolecularMutationNonsense CodonNonsense-Mediated DecayPathway interactionsPatientsPeptide Initiation FactorsPlayPoly(A) TailProcessProtein BindingProteinsQuality ControlRNARNA BindingRNA-Binding ProteinsRecruitment ActivityRelative (related person)RibosomesRoleSaccharomyces cerevisiaeSignal TransductionTerminator CodonTestingTrans-ActivatorsTranslatingTranslationsUntranslated RegionsYeastsbaseinnovationinsightmRNA Decaymessenger ribonucleoproteinnovelnovel strategiesnovel therapeutic interventionpolypeptideprematurepreventprotein protein interactionresponse
项目摘要
DESCRIPTION (provided by applicant): Degradation of mRNA plays an important role in regulating gene expression. In eukaryotic cells a specialized pathway has evolved to stimulate the degradation of aberrant mRNAs containing a premature nonsense codon (PTC), a signal that causes early termination of translation and, if left unchecked, the accumulation of truncated polypeptides. This pathway, referred to as nonsense- mediated mRNA decay (NMD), represents a conserved quality control mechanism that upholds fidelity and protects cells from erroneous gene expression. The widely accepted model for NMD posits that PTC-containing mRNA are recognized as aberrant due an impaired interaction between the terminating ribosome and the mRNA poly(A) tail-bound protein, PAB1, as a consequence of translation termination occurring too far away. Our observations challenge this paradigm and indicate that a model invoking a distance between the terminating ribosome and PAB1 as the critical determinant in NMD substrate recognition cannot sufficiently explain how cells discriminate between normal and premature translation termination. The long term goal of this proposal is to elucidate the molecular mechanisms underlying both recognition and rapid degradation of mRNA by the NMD pathway. We will address the important questions of how nonsense-containing mRNA are both recognized and targeted for rapid degradation under three specific aims. First, we will identify and characterize mRNP elements important for targeting PTC-containing mRNA to NMD. In addition, we propose two innovative and unbiased approaches to identify cis- and trans-acting antagonists of NMD. Second, we will investigate the requirements for assembly of NMD proteins with mRNA substrates. In particular, we will examine the order for protein assembly, whether binding targets are ribosomes, mRNA, or both, and particular mRNA features for their importance in NMD mRNP assembly. Finally we will also assess the functional capabilities of individual NMD proteins independent of their RNA binding capacities. Third, we will elucidate how recognition of a PTC- containing mRNA as aberrant is communicated to the cellular decay machinery and leads to accelerated degradation of the mRNA. Our preliminary data dispute a common belief that the NMD machinery directly recruits the decay machinery to the mRNA through conserved protein- protein interactions. We plan to further challenge this model as well as test our hypothesis that rapid mRNA decay is an indirect consequence of restricting translation initiation factor binding to the mRNA 52 cap.
描述(由申请人提供):mRNA的降解在调节基因表达中起重要作用。在真核细胞中,已经进化出一种专门的途径来刺激含有过早无义密码子(PTC)的异常mRNA的降解,PTC是一种导致翻译提前终止的信号,如果不加抑制,则会导致截短多肽的积累。该途径被称为无义介导的mRNA衰变(NMD),代表了保守的质量控制机制,其维持保真度并保护细胞免于错误的基因表达。广泛接受的NMD模型假定,含有PTC的mRNA被认为是异常的,这是由于终止核糖体和mRNA聚(A)尾结合蛋白PAB 1之间的相互作用受损,这是翻译终止发生得太远的结果。我们的观察结果挑战了这种范式,并表明,调用终止核糖体和PAB 1之间的距离作为NMD底物识别的关键决定因素的模型不能充分解释细胞如何区分正常和过早的翻译终止。该提案的长期目标是阐明NMD途径识别和快速降解mRNA的分子机制。我们将解决的重要问题,如何无义的mRNA都承认和有针对性的快速降解下三个具体目标。首先,我们将鉴定和表征mRNP元件,其对于将含有PTC的mRNA靶向NMD是重要的。此外,我们提出了两个创新的和公正的方法来确定顺式和反式作用的拮抗剂的NMD。第二,我们将研究NMD蛋白与mRNA底物组装的要求。特别是,我们将研究蛋白质组装的顺序,结合靶点是否是核糖体、mRNA或两者,以及特定mRNA特征在NMD mRNP组装中的重要性。最后,我们还将评估独立于其RNA结合能力的单个NMD蛋白的功能能力。第三,我们将阐明如何识别一个PTC-含有mRNA作为异常是沟通的细胞衰变机制,并导致加速降解的mRNA。我们的初步数据质疑一个共同的信念,即NMD机制直接招募衰变机制的mRNA通过保守的蛋白质-蛋白质相互作用。我们计划进一步挑战这一模型,以及测试我们的假设,即快速mRNA衰变是限制翻译起始因子结合mRNA 52帽的间接后果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristian Eileen Baker其他文献
Kristian Eileen Baker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristian Eileen Baker', 18)}}的其他基金
Recognition and degradation of mRNA by nonsense-mediated decay.
通过无义介导的衰变来识别和降解 mRNA。
- 批准号:
10458690 - 财政年份:2021
- 资助金额:
$ 28.79万 - 项目类别:
Recognition and degradation of mRNA by nonsense-mediated decay.
通过无义介导的衰变来识别和降解 mRNA。
- 批准号:
10279973 - 财政年份:2021
- 资助金额:
$ 28.79万 - 项目类别:
Recognition and degradation of mRNA by nonsense-mediated decay.
通过无义介导的衰变来识别和降解 mRNA。
- 批准号:
10629249 - 财政年份:2021
- 资助金额:
$ 28.79万 - 项目类别:
Recognition and degradation of mRNA by nonsense-mediated decay
无义介导的衰变对 mRNA 的识别和降解
- 批准号:
8692903 - 财政年份:2011
- 资助金额:
$ 28.79万 - 项目类别:
Recognition and degradation of mRNA by nonsense-mediated decay
无义介导的衰变对 mRNA 的识别和降解
- 批准号:
8025020 - 财政年份:2011
- 资助金额:
$ 28.79万 - 项目类别:
Recognition and degradation of mRNA by nonsense-mediated decay
无义介导的衰变对 mRNA 的识别和降解
- 批准号:
8334474 - 财政年份:2011
- 资助金额:
$ 28.79万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 28.79万 - 项目类别:
Research Grant